About Us About Us

Board of Directors


Peter J. Crowley

Chairman of the Board

Mr. Crowley is Operating Partner of MTS Health Partners, L.P., a New York based healthcare merchant bank, and an Operating Partner at JH Partners, a private equity firm, in which capacities he has served since 2011 and 2008, respectively.  Mr. Crowley retired in 2008 as Managing Director of the Healthcare Investment banking group at Oppenheimer & Company (formerly CIBC World Markets), which he headed since 1995, with responsibility for public and private financing and advisory services for biotechnology, pharmaceutical, medical device and healthcare services companies. Mr. Crowley serves on the board of directors of the Foundation Fighting Blindness; Woodbury Health Products Inc., a catheter distribution company; Anabios, a private biotechnology company; Celerion, a contract research organization; and Ouidad, Inc., a hair salon company.  Mr. Crowley holds an M.B.A. in finance from Columbia University Graduate School of Business and a B.A. in economics from Harvard University.


Mark R. Baker


Mr. Baker is Chief Executive Officer and a director of the Company. In 2005 Mr. Baker joined the Company as Senior Vice President & General Counsel and Secretary, in 2008 he became Executive Vice President, Corporate, in 2009 he became President of the Company and in March 2011 he was appointed Chief Executive of the Company. He became director of the Company in 2009. Prior to joining the Company Mr. Baker was Chief Business Officer and a director of New York Water Taxi, a privately-held ferry operation in New York City (2003-2005), Executive Vice President and Chief Legal Officer of Continental Grain Company, a privately-held international agri-business and financial concern (1997-2001) and a partner and Co-Chairman of the Capital Markets Group of Dewey Ballantine, a New York law firm (1979-1997). Mr. Baker serves as Chairman of the Board of Directors of the Brooklyn Bridge Park Conservancy. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.

Bradley Campbell

Bradley L. Campbell


Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics Inc., a biotechnology company focused on developing next generation therapies for rare diseases, and brings over 15 years of experience in the orphan drug industry. He is a member of the BioNJ Board of Directors and is Amicus’ representative on the Health Care Initiative of New Jersey Board of Trustees. Prior to Amicus, Mr. Campbell held positions of increasing responsibility at Genzyme and Bristol-Myers Squibb and as strategy consultant for Marakon Associates. He is also past President of the National Tay-Sach and Allied Diseases Association Board of Directors and currently services on their Corporate Advisory Council. Mr. Campbell received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.


Karen Jean Ferrante, M.D.


Dr. Ferrante joined our Board in January 2014. She was most recently head of Research and Development and Chief Medical Officer of Tokai Pharmaceuticals, Inc., which was a publicly traded biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From September 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Department. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. Prior to that, she was at the New England Deaconess Hospital in Boston (Beth Israel Deaconess), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at the Beth Israel Deaconess Hospital, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School, and previously was a Bacteriologist for the City of Providence, Rhode Island Water Supply Board. Dr. Ferrante holds a B.S. in Chemistry and Biology from Providence College and an M.D. from Georgetown University.


Michael D. Kishbauch


Mr. Kishbauch was elected to the Board in September 2013.  He has held senior management positions in the life sciences industry for almost three decades, with extensive operational, strategic, product planning and promotion, sales, marketing and product launch experience. Mr. Kishbauch was most recently President and Chief Executive Officer of Achillion Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2004 until his retirement in 2013. Prior to his work at Achillion, Mr. Kishbauch founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercial-stage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson & Johnson in 2003. He has previously held senior management positions with MedImmune, Inc .  Mr. Kishbauch continues to serve on Achillion’s board as a member of the Compliance Committee and currently serves on the Board as well as the Compensation and Audit Committees of Catabasis Pharmaceuticals, Inc., also a publicly traded biopharmaceutical company. He was a director of ARIAD Pharmaceuticals, Inc. from 2004 to 2008 and has held board positions with several other life sciences companies. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.


David A. Scheinberg M.D., Ph.D.


Dr. Scheinberg became a scientific advisor to Progenics in 1994 and joined our Board in 1996. He has been associated with the Sloan-Kettering Institute for Cancer Research since 1986, where he is the Vincent Astor Chair and Member, Leukemia Service; Chairman, Molecular Pharmacology Program; and Chairman, Experimental Therapeutics Center. He also holds the positions of Professor of Medicine and of Pharmacology at the Weill-Cornell Medical College of Cornell University and is a Founder and Director of the Tri-Institutional Therapeutics Discovery Institute, a non-profit drug development corporation formed by Sloan-Kettering, Cornell and The Rockefeller University since 2013. He received a B.A. from Cornell and an M.D. and a Ph.D. in pharmacology and experimental therapeutics from The Johns Hopkins University School of Medicine.


Nicole S. Williams M.B.A.


Ms. Williams was elected to our Board in 2007 after retiring in 2006 as Chief Financial Officer of Abraxis Bioscience Inc., a biopharmaceutical company, and President of its Abraxis Pharmaceutical Products division, positions she assumed upon the 2006 merger of American Pharmaceutical Partners, Inc. and American Bioscience Inc. From 2002 to 2006, Ms. Williams was the Executive Vice President and Chief Financial Officer of American Pharmaceutical Partners, as well as President from 2005. Previously, she was Executive Vice President and Chief Financial Officer of R.P. Scherer, Inc., a global drug delivery company. Ms. Williams is President of the Nicklin Capital Group, Inc., a firm she founded in 1999 to invest in and provide consulting to early-stage technology companies in the Midwest. She was a director and Audit Committee chair until November 2015 and a Compensation Committee member, at Intercept Pharmaceuticals, Inc., a publicly traded biotechnology company, and previously held the same positions, in addition to Nominating and Governance Committee chair, at Orchid Cellmark, Inc., a leading DNA identity testing service company, until its 2011 purchase by Laboratory Corporation of America Holdings. Ms. Williams received her Demi-License en Science Politique from the University of Geneva, Switzerland, her License en Science Politique from the Graduate Institute of International Affairs, University of Geneva, Switzerland and her M.B.A. from the Graduate School of Business, University of Chicago. She is a National Association of Corporate Directors (NACD) Board Leadership Fellow.